3,6-二溴吡嗪-2-胺 | 957230-70-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3,6-二溴吡嗪-2-胺
• 中文别名: 2,5-二溴-3-氨基吡嗪；2-氨基-3，6-二溴吡嗪
• 英文名称: 3,6-dibromopyrazin-2-amine
• CAS: 957230-70-5
• 化学式: C₄H₃Br₂N₃
• 分子量: 252.896
• InChiKey: ZEDFFSRZLCREEN-UHFFFAOYSA-N

物化性质

• 沸点：
  314℃
• 密度：
  2.287
• 闪点：
  144℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3,6-Dibromopyrazin-2-amine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3,6-Dibromopyrazin-2-amine
Ingredient name:
CAS number: 957230-70-5

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C4H3Br2N3
Molecular weight: 252.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,6-二溴吡嗪-2-胺 在 pyridine hydrofluoride 、 cesium fluoride 、 sodium nitrite 作用下， 以 1,3-二噁烷 为溶剂， 以90 %的产率得到2,5-dibromo-3-fluoropyrazine
  参考文献：
  名称：

  Dragmacidins G 和 H 的全合成

  摘要：

  使用适当功能化的吡嗪作为底物，通过亲核芳香取代和位点选择性交叉偶联反应，首次实现了德拉马西丁 G 和 H 的全合成。德拉马西丁 G、德拉马西丁 H 和合成类似物对金黄色葡萄球菌和外排泵缺陷型鼠伤寒沙门氏菌的抗菌活性评估表明，靠近硫化物单元的吲哚环上存在 Br 基团对于提高抗菌活性非常重要。

  DOI：

  10.1021/acs.orglett.3c04039
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3,6-二溴吡嗪-2-胺
  参考文献：
  名称：

  Discovery of a series of imidazopyrazine small molecule inhibitors of the kinase MAPKAPK5, that show activity using in vitro and in vivo models of rheumatoid arthritis

  摘要：

  MAPKAPK5 has been proposed to play a role in regulation of matrix metalloprotease expression and so to be a potential target for intervention in rheumatoid arthritis. We present here the identification of a series of compounds against this target which are effective in both biochemical and cell assays. The expansion of the series is described, along with early SAR and pharmacokinetics for some representative compounds. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.077
• 作为试剂：
  描述：

  2-氨基-3,5-二溴吡嗪 、 2-氨基吡啶-5-硼酸,频哪醇酯 、 disodium;carbonate 在 四(三苯基膦)钯 3,6-二溴吡嗪-2-胺 、 氮气 、 水 、 乙酸乙酯 、 Sodium sulfate-III 、 Dcm mtbe 作用下， 以 dioxane-water 为溶剂， 反应 16.17h， 以to give the title compound (11 g)的产率得到3-(4-Aminophenyl)-5-bromo-2-pyrazinamine
  参考文献：
  名称：

  AMINOPYRAZINE COMPOUNDS

  摘要：

  式(I)的化合物：其中所有符号的含义与说明书中定义的含义相同；其盐，溶剂化合物，N-氧化物或前药，具有Itk抑制活性，并且可用于预防和/或治疗特应性皮炎等疾病的方法。

  公开号：

  US20140187529A1

文献信息

• [EN] COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION<br/>[FR] COMPOSÉS ET LEUR UTILISATION DANS LE TRAITEMENT D'UNE INFECTION BACTÉRIENNE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021190727A1

  公开（公告）日：2021-09-30

  The invention provides novel compounds having the general formula (I) wherein R1, R2, R3a, R3b, R4, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, and L are as described herein, compositions including the compounds and methods of using the compounds.

  本发明提供了具有通式（I）的新颖化合物，其中R1、R2、R3a、R3b、R4、A1、A2、A3、A4、A5、A6、B1、B2、B3、B4和L如本文所述，以及包含这些化合物的组合物和使用这些化合物的方法。
• PYRAZINE GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
  申请人：Janssen Pharmaceutica NV

  公开号：US20160009662A1

  公开（公告）日：2016-01-14

  Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R 1 , G, and R 2 are defined herein.

  揭示了一种用于治疗受GPR40受体调节影响的疾病的化合物、组合物和方法。这些化合物由以下式（I）表示：其中R1、G和R2在此处定义。
• FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：Andrews Martin James Inglis

  公开号：US20090286798A1

  公开（公告）日：2009-11-19

  Novel[1.2.4]triazolo[1,5-a]pyrazine and imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.

  揭示了具有以下表示的公式的新型[1.2.4]三唑并咪唑[1,2-a]吡嗪化合物：这些化合物可以制备为药物组合物，并可用于哺乳动物包括人类的预防和治疗多种疾病，包括但不限于疼痛、炎症等。
• MRGX2 ANTAGONISTS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20220112174A1

  公开（公告）日：2022-04-14

  This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.

  本发明涉及按照式（I）的新化合物，这些化合物是MrgX2的拮抗剂，包含它们的药物组合物，以及它们在治疗MrgX2介导的疾病和疾病中的应用。
• INHIBITORS OF JAK
  申请人：de Vicente Fidalgo Javier

  公开号：US20110059118A1

  公开（公告）日：2011-03-10

  The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R′, X, X′, Y, Z 1 , Z 2 , and Z 3 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用式I的新化合物，其中变量m、n、p、q、Q、r、R、R′、X、X′、Y、Z1、Z2和Z3如本文所述定义，这些化合物抑制JAK并且对于治疗自身免疫和炎症性疾病有用。